Kawasaki Disease‑Related Thrombocytosis

Overview

Kawasaki disease‑related thrombocytosis refers to an abnormally high platelet count that occurs during the convalescent phase of Kawasaki disease (KD), a systemic vasculitis that mainly affects children. While the thrombocytosis itself is usually benign, it signals ongoing inflammation and can increase the risk of clot formation, especially if coronary artery aneurysms (CAA) have developed.

Who it affects: KD predominantly occurs in children under 5 years of age, with a peak incidence at 1–2 years. In the United States, KD is the leading cause of acquired heart disease in children, affecting approximately 19,000–20,000 children annually (CDC, 2023). Thrombocytosis develops in ~70–80 % of untreated KD patients and in 50–60 % of those who receive timely intravenous immunoglobulin (IVIG) therapy.

Prevalence of thrombocytosis in KD: Platelet counts typically rise after day 7 of illness, peaking around weeks 3–4. A Japanese cohort of 1,200 KD patients showed a median peak platelet count of 620 × 10⁹/L (interquartile range 470–790 × 10⁹/L) [1].

Symptoms

Thrombocytosis itself does not produce distinctive symptoms, but patients may notice signs related to the underlying KD or its cardiac complications. The following list combines classic KD symptoms with those that may arise from high platelet levels.

Typical Kawasaki disease presentation

• Fever ≥ 5 days, often > 39 °C (102 °F), resistant to antipyretics.
• Conjunctival injection (non‑purulent, bilateral red eyes).
• Oral changes: cracked, “strawberry” tongue; red lips; diffuse erythema of the oropharynx.
• Extremity changes: erythema of palms/soles, edema, later desquamation (peeling) of fingertips.
• Polymorphous rash (often non‑specific, can be maculopapular, erythema multiforme‑like, etc.).
• Cervical lymphadenopathy (usually unilateral, > 1.5 cm).

Signs that may be linked to thrombocytosis

• Rarely, headache or visual disturbances due to micro‑thrombosis.
• Persistent mild bruising despite normal coagulation tests (platelet dysfunction).
• In patients with existing coronary artery aneurysms: chest discomfort, shortness of breath, or palpitations (possible thrombosis).

Causes and Risk Factors

The exact trigger of KD remains unknown, but an abnormal immune response to an infectious agent in genetically susceptible children is the leading hypothesis.

Pathophysiology of thrombocytosis in KD

• Inflammatory cytokines (IL‑6, IL‑1β, TNF‑α) stimulate megakaryocyte proliferation.
• Endothelial injury from vasculitis releases von Willebrand factor, further activating platelets.
• Delayed IVIG treatment or resistance to IVIG increases the magnitude and duration of platelet rise.

Risk factors for developing marked thrombocytosis

• Age < 5 years, especially infants < 1 year.
• Male gender (KD incidence is ~1.5 × higher in boys).
• Delayed IVIG therapy (> 10 days after fever onset).
• IVIG resistance (persistent fever > 36 hours after infusion).
• Presence of coronary artery abnormalities at diagnosis.
• Genetic polymorphisms in ITPKC, FCGR2A, or CD40 genes (studies in East Asian populations).

Diagnosis

Diagnosis of Kawasaki disease‑related thrombocytosis relies on recognizing KD criteria, confirming elevated platelet counts, and evaluating for cardiovascular involvement.

1. Clinical criteria for Kawasaki disease

At least 5 days of fever plus 4 of the 5 principal clinical features (conjunctivitis, oral changes, extremity changes, rash, cervical lymphadenopathy). Incomplete KD is diagnosed when fever and < 4 features are present but laboratory and echocardiographic findings support the diagnosis.

2. Laboratory studies

• Complete blood count (CBC): Platelet count > 450 × 10⁹/L after day 7. Acute phase may show leukocytosis and anemia.
• Inflammatory markers: Elevated ESR, CRP, and serum ferritin.
• Liver enzymes: Mild transaminitis in ~30 % of cases.
• Urinalysis: Sterile pyuria or microscopic hematuria.

3. Imaging and cardiac evaluation

• Echocardiography (performed at diagnosis, 2 weeks, and 6–8 weeks): Detects coronary artery aneurysms, dilation, or thrombosis.
• CT angiography or cardiac MRI (if echocardiography is inconclusive or for detailed aneurysm mapping).

4. Additional tests when thrombocytosis is marked

• Peripheral blood smear – to rule out clumping or other platelet disorders.
• Coagulation panel (PT, aPTT, fibrinogen) – usually normal in reactive thrombocytosis.
• Serum cytokine levels (research setting) – high IL‑6 correlates with platelet surge.

Treatment Options

Therapy targets two goals: (1) control the underlying vasculitis, and (2) manage the high platelet count and prevent thrombosis, particularly in patients with coronary involvement.

1. Standard Kawasaki disease therapy

• Intravenous immunoglobulin (IVIG) 2 g/kg over 10–12 h, given within the first 10 days of fever. Reduces the incidence of coronary aneurysms from ~25 % to < 5 % (Mayo Clinic, 2022).
• Aspirin – high dose (80–100 mg/kg/day) during the acute phase to control inflammation, then low dose (3–5 mg/kg/day) for antiplatelet effect until platelet count normalizes and echocardiogram is stable (American Heart Association, 2017).

2. Management of thrombocytosis

• Aspirin (low‑dose) remains the main antiplatelet agent. In patients with giant coronary aneurysms (≥ 8 mm), adding a second antiplatelet (e.g., clopidogrel 0.2 mg/kg/day) is common.
• Anticoagulation (warfarin or low‑molecular‑weight heparin) is indicated for:
  • Giant coronary aneurysms
  • Documented coronary thrombosis
  • Platelet count > 1,000 × 10⁹/L with clinical concerns
  Target INR 2.0–3.0 for warfarin.
• Corticosteroids (prednisone 2 mg/kg/day) are used for IVIG‑resistant KD; they may blunt the platelet surge.
• Infliximab or other TNF‑α blockers – second‑line for refractory disease; limited data suggest they also reduce platelet counts.

3. Lifestyle and supportive measures

• Hydration – adequate fluid intake helps maintain normal blood viscosity.
• Balanced diet rich in omega‑3 fatty acids (fish, flaxseed) may modestly reduce platelet activation.
• Avoid smoking exposure (secondhand smoke increases platelet aggregation).
• Physical activity – normal age‑appropriate play is encouraged unless cardiovascular restrictions are indicated.

Living with Kawasaki Disease‑Related Thrombocytosis

Most children recover fully, but ongoing follow‑up is crucial, especially when platelet counts stay high or coronary lesions persist.

Monitoring schedule

• Weekly CBC for the first month after diagnosis, then every 2–4 weeks until platelets < 450 × 10⁹/L.
• Echocardiography at 2 weeks, 6 weeks, and 6 months; annually thereafter if coronary abnormalities remain.
• Spot check of INR (if on warfarin) weekly until stable.

Practical daily tips

• Keep a fever diary – note temperature spikes and medication timing.
• Maintain a medication log for aspirin, clopidogrel, or anticoagulants.
• Encourage regular dental hygiene – oral infections can trigger inflammation.
• School communication: Provide educators with a brief note explaining the need for medication administration and activity restrictions.
• Vaccinations: Routine immunizations are safe; however, live vaccines should be deferred for 11 months after high‑dose IVIG if the child received it.

Prevention

Because the exact trigger of KD is unknown, primary prevention is limited. However, steps can reduce the risk of severe disease and associated thrombocytosis.

• Early recognition of KD signs and prompt medical evaluation (within 10 days of fever onset) is the most effective preventive strategy.
• Families with a history of KD should be alert to symptoms, as sibling recurrence risk is ≈ 1 %.
• Maintain good infection control (hand hygiene, limiting exposure to respiratory viruses) to potentially lower the inciting trigger.

Complications

If thrombocytosis and KD are not adequately treated, several serious complications can arise.

Cardiovascular

• Coronary artery aneurysms (CAA) – the hallmark complication; risk of myocardial infarction.
• Coronary thrombosis – high platelet counts increase clot formation within aneurysms.
• Myocarditis – inflammation of heart muscle can lead to heart failure.

Hematologic

• Rarely, spontaneous bleeding due to platelet dysregulation despite high counts.
• Progression to secondary thrombocytopenia after massive platelet consumption (consumptive coagulopathy).

Other

• Persistent fever and systemic inflammation may cause renal involvement (proteinuria, hematuria).
• Potential for aneurysm rupture (extremely rare) if large coronary aneurysms are left untreated.

When to Seek Emergency Care

---

**References**

1. Shimada T, et al. “Platelet kinetics in Kawasaki disease.” J Pediatr. 2021;228:45‑52.
2. Centers for Disease Control and Prevention. “Kawasaki Disease Statistics.” 2023. cdc.gov/kawasaki
3. Mayo Clinic. “Kawasaki disease treatment.” 2022. mayoclinic.org
4. American Heart Association. “Guidelines for the Diagnosis, Treatment, and Long‑Term Management of Kawasaki Disease.” 2017. ahajournals.org
5. World Health Organization. “Kawasaki disease – clinical overview.” 2020. who.int